Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus May 08, 2018 Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets May 03, 2018 Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting Apr 30, 2018 New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors Apr 24, 2018 Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018 Apr 15, 2018 Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors Apr 11, 2018 Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb Apr 03, 2018 Nektar to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference in Boston Mar 07, 2018 Nektar Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results Mar 01, 2018 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2017 on Thursday, March 1, 2018, After Close of U.S.-Based Financial Markets Feb 21, 2018 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »